【Objective】 To investigate the safety and benefit of doxorubicin loaded hydrophobic linear alkyl modified graphene oxide （DOX@GO- C18） served as vectors in transcatheter arterial chemoembolization （TACE）. 【Methods】 Doxorubicin loaded hydrophobic linear alkyl modified graphene oxide was manufactured and characterized. VX2 liver carcinoma was established in rabbits and the hepatic lesions were treated with TACE using DOX@GO- C18 which was dissolved in lipiodol. Pre- and post- CT scans were performed to evaluate the treatment response. Liver function was assessed via blood samples drawn on day 0（preoperative），1，3，7，and day 14. The animals were sacrificed on day 14 and tissue samples collected to stain for pathology（hematoxylin-eosin staining），lipiodol（oil red O staining）and DOX（fluorescent）.【Results】The dispersion of DOX@GO-C18 in lipiodol was highly stable. Pre-and post-CT scan revealed that the diameter of the VX2 lesions barely varied and enhancements were decreased after the treatment. Target lesions gained stable disease（SD）as the treatment response based on Response Evaluation Criteria in Solid Tumors 1.1（RECIST 1.1）. Histological examination revealed that DOX@GO-C18 was located within the tumor tissue along with the lipiodol. The release of DOX may contribute to the necrosis in tumor.【Conclusions】DOX@GO-C18［CC2］may proved to be a safe and effective vectors in TACE treatment for liver carcinoma.